How are energy investors positioned?
In a challenging market environment, Clene Inc. (CLNN) stock has reached its 52-week low, trading at $2.5. With a market capitalization of just $23.36 million and negative EBITDA of -$26.31 million, this significant downturn reflects a broader trend for the biopharmaceutical company, which has seen its stock price plummet by 64.31% over the past year. Investors have been cautious as the company navigates through a complex landscape of regulatory hurdles and competitive pressures, contributing to the stock’s underperformance. InvestingPro analysis reveals the company is quickly burning through cash, with analysts anticipating sales decline in the current year. The 52-week low serves as a critical indicator for shareholders and potential investors, signaling a period of heightened scrutiny and consideration for the company’s future prospects and strategic direction. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial metrics to make better-informed investment decisions.
In other recent news, Clene Inc. reported its fourth-quarter and full-year financial results for 2024, revealing earnings per share of ($1.61) for the fourth quarter and ($5.67) for the year, which fell short of analyst expectations. The company ended the year with a cash position of $12.2 million, anticipated to support operations until the second quarter of 2025. Clene also announced significant findings from its VISIONARY-MS Trial extension study, showcasing improvements in multiple sclerosis patients treated with CNM-Au8, indicating potential neuronal repair and remyelination. The company further resolved a $125,000 debt by issuing 35,311 shares of common stock at $3.54 per share, aiming to strengthen its balance sheet without additional cash expenditures. Additionally, Clene entered an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $25 million of its common stock, potentially raising capital as needed. H.C. Wainwright maintained its Buy rating and a $31 price target on Clene stock, citing the promising results of CNM-Au8 in ALS trials. The firm noted that the data supports ongoing discussions with the FDA for potential accelerated approval. Clene plans to continue its development of CNM-Au8, with a Phase 3 RESTORE-ALS study expected to begin in mid-2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.